Abstract
Aim:
To prepare a redispersible, dry emulsion (DE) and investigate whether it can improve intestinal stability and oral absorptive efficiency of the poorly water-soluble lovastatin (Lov).
Methods:
Phosal 53 MCT, Tween 80, and starch sodium octenyl succinate were employed as the oil phase, emulsifying agent, and matrix material, respectively. The redispersible, DE of Lov (Lov-DE) was prepared by spray drying the submicron emulsion of Lov. The characteristics of DE and the in vitro drug release were studied. The protective effects on the metabolism of Lov-DE and reference formulations, including the Lov suspension and the hydroxypropyl–β-cyclodextrin (CD) complex were investigated in microsomes and the gut wall of male Sprague–Dawley (SD) rats. The bioavailability in SD rats was evaluated simultaneously.
Results:
Lov-DE in distilled water was reconstituted compared with the submicron emulsion of Lov before spray drying, and remained almost unchanged after 3 months' storage at room temperature. Compared with the Lov suspension, the in vitro Lov dissolution of both the redispersible, DE and CD complex increased obviously. Compared with control formulations, the metabolism studies carried out in vitro and in vivo confirmed that the redispersible, DE presented remarkable protective effects as indicated by the decreased metabolism rate of Lov. Lov-DE showed a 1.83-fold and 1.44-fold higher the area under the curve(AUC0-8h)of Lov compared with that of the Lov suspension and CD complex in SD rats, respectively.
Conclusion:
Lov-DE reduced the metabolism of Lov in the small intestine and improved its oral absorption in SD rats.
Similar content being viewed by others
Article PDF
References
Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, et al. Mevinolin: a highly potent competitive inhibitor of hydroxyl-methylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 1980; 77: 3957–61.
Reinoso RF, Sánchez Navarro A, García MJ, Prous JR, et al. Preclinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 2002; 24: 593–613.
Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, et al. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin. J Pharmacol Exp Ther 1999; 291: 131–9.
Zhang Y, Benet LZ . The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40: 159–68.
Patel RP, Patel MM . Physicochemical characterization and dissolution study of solid dispersions of Lovastatin with polyethylene glycol 4000 and polyvinylpyrrolidone K30. Pharm Dev Technol 2007; 12: 21–33.
Jun SW, Kim MS, Kim JS, Park HJ, Lee S, Woo JS, et al. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm 2007; 66: 413–21.
Suresh G, Manjunath K, Venkateswarlu V, Satyanarayana V . Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech 2007; 8: E162–E170.
Charman WN, Porter CJH, Mithani S, Dressman JB . Physico-chemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci 1997; 86: 269–82.
Daher CF, Baroody GM, Howland RJ . Effect of a surfactant, Tween 80, on the formation and secretion of chylomicrons in the rat. Food Chem Toxicol 2003; 41: 575–82.
Wang SW, Monagle J, McNulty C, Putnam D, Chen H . Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process. J Pharm Sci 2004; 93: 2755–67.
Rege BD, Kao JP, Polli JE . Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 2002; 16: 237–46.
Dollo G, Le Corre P, Guérin A, Chevanne F, Burgot JL, Leverge R . Spray-dried redispersible oil-in-water emulsion to improve oral bioavailability of poorly soluble drugs. Eur J Pharm Sci 2003; 19: 273–80.
Tue H, Per H, Morten R, Kirsten S . In vivo evaluation of tablets and capsules containings spray-dried o/w emulsions for oral delivery of poorly soluble drugs. Int J Pharm 2005; 293: 203–11.
Dixit RP, Nagarsenker MS . Dry adsorbed emulsion of simvastatin: optimization and in vivo advantage. Pharm Dev Technol 2007; 12: 495–504.
Chambin O, Bérard V, Rochat-Gonthier MH, Pourcelot Y . Dry adsorbed emulsion: 2. Dissolution behaviour of an intricate formulation. Int J Pharm 2002; 235: 169–78.
Chen CM, Chou J, Wong D . Improved HMG-CoA reductase inhibitor extended release formulation. US patent 5 916 595. 1998 Dec 04.
Duggan DE, Bayne WF, Halpin RA, Duncan CA, Schwartz MS, et al. The physiological disposition of lovastatin. Drug Metab Dispos 1989; 17: 166–73.
Stubbs RJ, Schwartz M, Bayne WF . Determination of mevinolin and mevinolinic acid in plasma and bile by reversed-phase high-performance liquid chromatography. J Chromatogr 1986; 383: 438–43.
World Health Organization. Toxicological evaluation of certain food additives (Starch sodium octenyl succinate). WHO Food Additives Series 1982; 17: 541.
Gershanik T, Benita S . Self-dispersing lipid formulations for improving Coral absorption of lipophilic drugs. Eur J Pharm Biopharm 2000; 50: 179–88.
Pouton CW . Lipid formulations for oral administration of drugs non-emulsifying, self-emulsifying and self-microemulsifying drug delivery systems. Eur J Pharm Sci 2000; 11 Suppl 2: S93–8.
Mountfield RJ, Senepin S, Schleimer M, Walter I, Bittner B . Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450. Int J Pharm 2000; 211: 89–92.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by the National Natural Sciences Foundation of China (No 30701054) and the New Drug Basic Research Program of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (No 07G603 H071).
Rights and permissions
About this article
Cite this article
Ge, Z., Zhang, Xx., Gan, L. et al. Redispersible, dry emulsion of lovastatin protects against intestinal metabolism and improves bioavailability. Acta Pharmacol Sin 29, 990–997 (2008). https://doi.org/10.1111/j.1745-7254.2008.00825.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2008.00825.x
Keywords
This article is cited by
-
Evaluation of Spray BIO-Max DIM-P in Dogs for Oral Bioavailability and in Nu/nu Mice Bearing Orthotopic/Metastatic Lung Tumor Models for Anticancer Activity
Pharmaceutical Research (2015)
-
Transforming Lipid-Based Oral Drug Delivery Systems into Solid Dosage Forms: An Overview of Solid Carriers, Physicochemical Properties, and Biopharmaceutical Performance
Pharmaceutical Research (2013)
-
Phospholipids and Lipid-Based Formulations in Oral Drug Delivery
Pharmaceutical Research (2010)